SequelSEC

PTC THERAPEUTICS, INC. PTCT

Pharmaceutical Preparations · CIK 0001070081 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.16B
Fiscal year ended 2026-09-30
Operating income
$147.70M
Fiscal year ended 2026-09-30
Free cash flow
$2.07M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$3.35MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.04Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income0.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue0.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin50.1%100th
FCF margin40.6%96th
Net margin39.4%94th
Revenue YoY growth114.5%84th
SBC / revenue4.3%17th
R&D / revenue26.3%27th
Effective tax rate2.0%27th
CapEx / revenue0.5%31th
Current ratio2.35x32th

PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.16B and net income of -$105.97M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PTC THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PTC THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$1.16B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$147.70M
Net income-$105.97M
Research & development$438.50M
Weighted-average diluted sharesUnavailable
Pretax income-$85.09M
Income tax expense$20.88M
Diluted EPSUnavailable
Selling, general & administrative$343.77M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

PTC THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$508.89M
Total assets$3.21B
Current assets$2.54B
Total liabilities$3.40B
Current liabilities$776.08M
Total equity incl. NCI-$191.21M
Temporary (mezzanine) equityUnavailable
Inventory$109.33M
Accounts receivable$238.07M
Goodwill$82.34M
Long-term debt$536.27M
Accounts payable$41.59M

Cash flow

PTC THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow$10.49M
Capital expenditures$8.42M
Investing cash flow-$624.70M
Financing cash flow$447.55M
Net change in cash-$160.96M
Stock-based compensation$89.06M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$61.01M

Derived

PTC THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow$2.07M
Gross marginUnavailable
Operating margin12.8%
FCF margin0.2%
SBC / revenue7.7%
Current ratio3.27x
Revenue YoY growth-35.1%
Net margin-9.2%
R&D / revenue37.9%
CapEx / revenue0.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PTCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.